Fintel reports that on January 21, 2025, Cantor Fitzgerald downgraded their outlook for Keros Therapeutics (NasdaqGM:KROS) ...

H.C. Wainwright maintained a positive outlook on Axsome Therapeutics (NASDAQ:AXSM), reiterating a Buy stock rating with a ...

TORONTO, Jan. 22, 2025 /CNW/ - Mackenzie Investments ("Mackenzie") today released its 2025 ETF Outlook (the "Outlook"), examining the growth of the exchange-traded funds ("ETF") industry in Canada ...

The Bitcoin market continues to see a lot of noisy trading, but more than anything else, this is a market that will continue to see buyers on dips, as the market remains very stout overall. At this ...

Odyssey Therapeutics is a promising biotech firm poised for IPO success with a focus on inflammatory and autoimmune diseases like ulcerative colitis. Read the pre-IPO report here.

In our Energy Outlook, we detail our forecasts on fossil fuel, renewables, carbon capture and storage, hydrogen, and utilities ...

Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP ...